ESLA (Estrella Immunopharma) EBITDA Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESLA Estrella Immunopharma Inc ESLA
12 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Estrella Immunopharma EBITDA Margin %?

Estrella Immunopharma ESLA -1.11% 12 EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus rates ESLA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Estrella Immunopharma ranks worse than 106157.01% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Estrella Immunopharma's EBITDA for the three months ended in Jun. 2026 was $-2.08 Mil. Estrella Immunopharma's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Estrella Immunopharma's EBITDA margin for the quarter that ended in Jun. 2026 was 0.00%.

Estrella Immunopharma  (NAS:ESLA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Estrella Immunopharma EBITDA Margin % Related Terms

Estrella Immunopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Estrella Immunopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Estrella Immunopharma EBITDA Margin % Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00 0.00

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ESLA vs LITS, NNVC, LTRN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Estrella Immunopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Estrella Immunopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's EBITDA Margin % falls into.


ESLA
12GF Score
Estrella Immunopharma Inc ESLA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Estrella Immunopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Estrella Immunopharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-13.063/0
= %

Estrella Immunopharma's EBITDA Margin % for the quarter that ended in Jun. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-2.084/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Estrella Immunopharma (ESLA) has a EBITDA Margin % of 0.00% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Estrella Immunopharma and its competitors. According to the industry distribution chart, Estrella Immunopharma ranks #999999 out of 942 companies in the Biotechnology industry.
Is Estrella Immunopharma's EBITDA Margin % too high?
Estrella Immunopharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Estrella Immunopharma ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Estrella Immunopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Estrella Immunopharma's EBITDA Margin % compare to LITS and NNVC?
According to the Biotechnology industry distribution chart, Estrella Immunopharma ranks #999999 out of 942 companies for EBITDA Margin %. This places Estrella Immunopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Estrella Immunopharma and its competitors. Estrella Immunopharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Estrella Immunopharma stock overvalued right now?
Estrella Immunopharma (ESLA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Estrella Immunopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Estrella Immunopharma (ESLA), the current EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Estrella Immunopharma Business Description

Address 5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
12GF Score

Get the complete analysis for ESLA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price